A vaccines-focused expert roundup highlights areas where researchers expect meaningful progress in 2026, reinforcing that platform technologies and trial execution will drive the next wave of impact.
What’s driving the next wave
- improved delivery and stability
- broader antigen targets
- better manufacturing scalability
- faster trial pathways (where appropriate)
Realistic expectations
Breakthroughs often arrive as:
- stronger Phase 2 signals,
- better durability data,
- improved safety profiles,
not overnight global rollouts.
About the Author
